NTLA Stock Overview
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics.
Intellia Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$47.74|
|52 Week High||US$202.73|
|52 Week Low||US$38.85|
|1 Month Change||-12.95%|
|3 Month Change||-44.82%|
|1 Year Change||-24.80%|
|3 Year Change||221.48%|
|5 Year Change||259.76%|
|Change since IPO||116.02%|
Recent News & Updates
Intellia Therapeutics: Several Catalysts Expected For H2 2022
Intellia Therapeutics reported a loss of -$144M in Q1-2022. Further data on NTLA-2001 to be announced in the second half of June at the "EASL International Liver Congress" Preliminary results for NTLA-2002 expected for H2-2022. Liquidity is not at issue.
|NTLA||US Biotechs||US Market|
Return vs Industry: NTLA underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: NTLA underperformed the US Market which returned -12.9% over the past year.
|NTLA Average Weekly Movement||14.6%|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.0%|
Stable Share Price: NTLA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: NTLA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders.
Intellia Therapeutics Fundamentals Summary
|NTLA fundamental statistics|
Is NTLA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NTLA income statement (TTM)|
|Cost of Revenue||US$313.63m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-4.86|
|Net Profit Margin||-973.48%|
How did NTLA perform over the long term?See historical performance and comparison
Is Intellia Therapeutics undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NTLA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NTLA's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: NTLA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: NTLA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NTLA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NTLA is overvalued based on its PB Ratio (3.8x) compared to the US Biotechs industry average (1.5x).
How is Intellia Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NTLA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NTLA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NTLA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NTLA's revenue (71.2% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: NTLA's revenue (71.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NTLA's Return on Equity is forecast to be high in 3 years time
How has Intellia Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NTLA is currently unprofitable.
Growing Profit Margin: NTLA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NTLA is unprofitable, and losses have increased over the past 5 years at a rate of 35.8% per year.
Accelerating Growth: Unable to compare NTLA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NTLA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: NTLA has a negative Return on Equity (-38.64%), as it is currently unprofitable.
How is Intellia Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: NTLA's short term assets ($875.4M) exceed its short term liabilities ($126.1M).
Long Term Liabilities: NTLA's short term assets ($875.4M) exceed its long term liabilities ($122.9M).
Debt to Equity History and Analysis
Debt Level: NTLA is debt free.
Reducing Debt: NTLA has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NTLA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NTLA has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 39.3% each year.
What is Intellia Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NTLA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NTLA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NTLA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NTLA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NTLA has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Leonard (64 yo)
Dr. John M. Leonard, M.D., is an Executive Partner at Tyree & D'Angelo Partners. He has been a Director at IQVIA Holdings Inc. since February 2015 and has been its Lead Director since July 25, 2018. Dr. Le...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD9.77M) is above average for companies of similar size in the US market ($USD6.86M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
Experienced Management: NTLA's management team is considered experienced (3.6 years average tenure).
Experienced Board: NTLA's board of directors are considered experienced (7.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.3%.
Intellia Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Intellia Therapeutics, Inc.
- Ticker: NTLA
- Exchange: NasdaqGM
- Founded: 2014
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$3.621b
- Shares outstanding: 75.85m
- Website: https://www.intelliatx.com
Number of Employees
- Intellia Therapeutics, Inc.
- 40 Erie Street
- Suite 130
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/21 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.